Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Average Recommendation of “Buy” by Analysts

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) has been assigned a consensus rating of “Buy” from the eight research firms that are currently covering the company, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $5.50.

RVPH has been the subject of a number of recent research reports. Roth Capital reiterated a “buy” rating and issued a $3.00 price objective (down from $7.00) on shares of Reviva Pharmaceuticals in a report on Monday, August 18th. Maxim Group decreased their target price on Reviva Pharmaceuticals from $5.00 to $2.00 and set a “buy” rating for the company in a research report on Friday, August 15th. D. Boral Capital reiterated a “buy” rating and set a $3.00 price target on shares of Reviva Pharmaceuticals in a report on Monday, August 18th. Wall Street Zen upgraded shares of Reviva Pharmaceuticals to a “sell” rating in a research note on Saturday, August 16th. Finally, Citigroup reiterated a “buy” rating on shares of Reviva Pharmaceuticals in a research note on Friday, August 15th.

Institutional Investors Weigh In On Reviva Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Ameriprise Financial Inc. bought a new position in Reviva Pharmaceuticals during the fourth quarter worth $84,000. BluePointe Capital Management LLC grew its position in Reviva Pharmaceuticals by 354.7% in the 1st quarter. BluePointe Capital Management LLC now owns 47,185 shares of the company’s stock worth $45,000 after purchasing an additional 36,807 shares during the last quarter. NewEdge Advisors LLC bought a new position in shares of Reviva Pharmaceuticals during the 1st quarter worth about $58,000. XTX Topco Ltd bought a new position in shares of Reviva Pharmaceuticals during the 2nd quarter worth about $31,000. Finally, Private Advisor Group LLC acquired a new position in shares of Reviva Pharmaceuticals during the first quarter valued at about $191,000. 63.18% of the stock is owned by institutional investors.

Reviva Pharmaceuticals Price Performance

NASDAQ RVPH opened at $0.40 on Thursday. The firm has a market capitalization of $27.49 million, a price-to-earnings ratio of -0.62 and a beta of -0.04. The company has a 50 day simple moving average of $0.45 and a 200-day simple moving average of $0.69. Reviva Pharmaceuticals has a 52-week low of $0.30 and a 52-week high of $4.28.

Reviva Pharmaceuticals (NASDAQ:RVPH) last released its earnings results on Thursday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.03. On average, analysts predict that Reviva Pharmaceuticals will post -0.97 EPS for the current year.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.